Eisai files lenvatinib in rare thyroid indication
This article was originally published in Scrip
Eisai has filed its novel targeted anticancer lenvatinib (E7080) for approval in the US, EU and Japan on the basis of its SELECT study in progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC), its first markets. The first submission was made in Japan in June, followed by the US and EU this month.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.